For outcome · patients with rheumatoid arthritis in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ACR 50% improvement · patients with rheumatoid arthritis in adults
Summary of findings: leflunomide + methotrexate leads to higher ACR 50 at 6 months compared with methotrexate, 6 months (high certainty).
1 finding from 1 review
HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults
1 finding from 1 review
Intervention not reported
Pulmonary Methotrexate pneumonitis · patients with inflammatory arthritis on methotrexate
1 finding from 1 review
Intervention not reported
Withdrawal due to adverse events Methotrexate discontinuation · patients with inflammatory arthritis on methotrexate
1 finding from 1 review
Muscle strength · people with inclusion body myositis
2 findings from 1 review
Change in muscle mass at 12 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in grip strength · people with inclusion body myositis
1 finding from 1 review
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Significant adverse events · people with inclusion body myositis
1 finding from 1 review
Treatment responsea · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sustained clinically inactive diseasec · children and young people with JIA
Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in sustained clinically inactive diseaseb(12 months) compared with intra‐articular glucocorticoid alone (low certainty).
1 finding from 1 review
Function · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global well‐being: rated by participants · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events(12 months) · children and young people with JIA
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · children and young people with JIA
Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in withdrawals due to adverse events(12 months) compared with intra‐articular glucocorticoid alone (low certainty).
1 finding from 1 review
OutcomesTime frame of absolute effects · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review